CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19 - 29/11/22
Doi : 10.1016/j.jinf.2022.09.029
Ida Gregersen a, ⁎ 
, Thor Ueland a, b, c, Jan Cato Holter b, n, Maria Belland Olsen a, Annika E Michelsen a, b, Sarah L Murphy a, b, Anders Aune Tveita d, e, Katerina Nezvalova Henriksen f, g, Hedda Hoel a, b, h, Lena Bugge Nordberg r, Aleksander Rygh Holten b, i, Thor Edvardsen j, Kuan Yang a, Lars Heggelund k, l, Marius Trøseid a, b, m, Fredrik Müller b, n, Anders Benjamin Kildal o, Anne Ma Dyrhol-Riise b, p, Andreas Barratt-Due e, q, Tuva B Dahl a, i, Pål Aukrust a, b, m, Bente Halvorsen a, b
for the
, Thor Ueland a, b, c, Jan Cato Holter b, n, Maria Belland Olsen a, Annika E Michelsen a, b, Sarah L Murphy a, b, Anders Aune Tveita d, e, Katerina Nezvalova Henriksen f, g, Hedda Hoel a, b, h, Lena Bugge Nordberg r, Aleksander Rygh Holten b, i, Thor Edvardsen j, Kuan Yang a, Lars Heggelund k, l, Marius Trøseid a, b, m, Fredrik Müller b, n, Anders Benjamin Kildal o, Anne Ma Dyrhol-Riise b, p, Andreas Barratt-Due e, q, Tuva B Dahl a, i, Pål Aukrust a, b, m, Bente Halvorsen a, bfor the
NOR-SOLIDARITY consortium, The Norwegian SARS-CoV-2 Study Group investigators
a Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo 0027, Norway
b Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo 0318, Norway
c Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway
d Department of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum 1346, Norway
e Division of Laboratory Medicine, Department of Immunology, Oslo University Hospital, Oslo 0424, Norway
f Department of Hematology, Oslo University Hospital, Oslo, Norway
g Hospital Pharmacies, South-Eastern Norway Enterprise, Oslo, Norway
h Medical Department, Lovisenberg Diaconal Hospital, Oslo, Norway
i Department of Acute Medicine, Oslo University Hospital, Oslo, Norway
j Department of Cardiology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
k Department of Internal Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Drammen 3004, Norway
l Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen 5009, Norway
m Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway
n Department of Microbiology, Oslo University Hospital, Oslo 0424, Norway
o Department of Anesthesiology and Intensive Care, University Hospital of North Norway, Tromsø, Norway
p Department of Infectious Diseases, Oslo University Hospital, Ullevål, Oslo, Norway
q Department of Anaesthesia and Intensive Care Medicine, Oslo University Hospital, Oslo, Norway
r Medical Department, Diakonhjemmet Hospital, Oslo, Norway
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | CXCL16 correlates to severity of Covid-19. |
• | CXCL16 associates with cardiac risk markers. |
• | CXCL16 predicts risk of 60 days mortality. |
Keywords : Infection, SARS-CoV-2, Heart, Severity, Chemokines
© 2022
Publié par Elsevier Masson SAS.
Vol 85 - N° 6
P. 702-769 - décembre 2022 Retour au numéro
Article précédent
- Novel HIV-1 A6/B recombinant forms (CRF133_A6B and URF_A6/B) circulating in Krasnoyarsk region, Russia
- Lada V Maksimenko, Mariya V Sivay, Alexei V Totmenin, Alexander N Shvalov, Sergey E Skudarnov, Tatyana S Ostapova, Svetlana V Yaschenko, Rinat A Maksutov, Natalya M Gashnikova
- Aneuploidy underlies paradoxical growth of rezafungin and enables cross-tolerance to echinocandins in Candida albicans
- Hao Li, Yong-bing Cao, Tian-hua Yan, Yuan-ying Jiang, Feng Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.